Brian Gill
YOU?
Author Swipe
View article: Clinical Utility of [F18]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma
Clinical Utility of [F18]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma Open
[F18]-FACBC and [F18]-Fluciclovine＝ Trans-1-amino-3-[F18]-fluorocyclobutane-1-carboxylic acid; GBM＝glioblastoma; IDH＝Isocitrate Dehydrogenase; SUVmax＝maximum standardized uptake value.
View article: Seizure Outcomes as an Understudied Metric in Glioma Clinical Trials: A Review of the ClinicalTrials.gov Database
Seizure Outcomes as an Understudied Metric in Glioma Clinical Trials: A Review of the ClinicalTrials.gov Database Open
Background Seizures are a common and disabling symptom of adult-type diffuse gliomas, affecting quality of life and potentially influencing tumor progression. Despite their clinical significance, seizure outcomes are often underreported or…
View article: DDDR-56. Single-cell analysis of drug perturbations in IDH-mutant glioma
DDDR-56. Single-cell analysis of drug perturbations in IDH-mutant glioma Open
IDH-mutant gliomas are the most common malignant brain tumor in patients under 50 years old and have no cure. A major challenge in treatment is intratumoral heterogeneity, where drug-resistant subpopulations drive recurrence. Ferroptosis, …
View article: TMIC-111. Intraoperative 5-Aminolevulinic Acid (5ALA) fluorescence distinguishes cellular composition and immunogenicity in the infiltrating margin of Glioblastoma
TMIC-111. Intraoperative 5-Aminolevulinic Acid (5ALA) fluorescence distinguishes cellular composition and immunogenicity in the infiltrating margin of Glioblastoma Open
INTRODUCTION Glioblastoma (GBM) is a Grade 4 malignancy with a poor prognosis. The lethality of GBM is rooted in its ability to traverse parenchyma beyond resection margins, appearing continuous with normal parenchyma. Extent of resection …
View article: CNSC-65. THE EFFECT OF PERITUMORAL NEURONAL MTOR INHIBITION ON PERITUMORAL GABAERGIC TONE, PERITUMORAL EXCITABILITY AND NEURON-DRIVEN GLIOMA GROWTH
CNSC-65. THE EFFECT OF PERITUMORAL NEURONAL MTOR INHIBITION ON PERITUMORAL GABAERGIC TONE, PERITUMORAL EXCITABILITY AND NEURON-DRIVEN GLIOMA GROWTH Open
Tumor-induced decreases in inhibitory GABAergic tone contribute to cortical excitability, which may clinically manifest as seizures and interictal epileptiform discharges (IEDs). Tumor-associated epileptic events are often refractory to an…
View article: CNSC-60. STIMULUS-EVOKED INCREASES IN INTRACELLULAR CALCIUM PROMOTE SUSCEPTIBILITY TO FERROPTOSIS IN GLIOMA CELLS
CNSC-60. STIMULUS-EVOKED INCREASES IN INTRACELLULAR CALCIUM PROMOTE SUSCEPTIBILITY TO FERROPTOSIS IN GLIOMA CELLS Open
Gliomas integrate within neural networks and receive synaptic input from neurons. We recently reported that sensory stimulus-evoked neuronal activity can elicit cytosolic calcium transients in glioma cells. It is known that perturbing calc…
View article: CNSC-57. HUMAN AND MOUSE PERITUMORAL SLICES DEMONSTRATE MTOR-DEPENDENT GABAERGIC NEURONAL DYSFUNCTION IN GLIOMA
CNSC-57. HUMAN AND MOUSE PERITUMORAL SLICES DEMONSTRATE MTOR-DEPENDENT GABAERGIC NEURONAL DYSFUNCTION IN GLIOMA Open
Approximately 60-80% of all glioma patients experience seizures, and a significant number of these patients are unable to achieve seizure freedom with conventional anti-epileptic treatment alone. One suggested mechanism for these tumor-ass…
View article: TMET-43. IDH1(R132H) inhibitors enhance the sensitivity of IDH1-mutant glioma to cysteine deprivation and ferroptosis
TMET-43. IDH1(R132H) inhibitors enhance the sensitivity of IDH1-mutant glioma to cysteine deprivation and ferroptosis Open
Cysteine is a key molecule in the production of glutathione, the main antioxidant in the brain, and cysteine deprivation has been shown to sensitize cells to ferroptosis. In this study, using a newly developed mouse model of IDH1(R132H) gl…
View article: CTNI-37. SONOBIRD: A PHASE 3 TRIAL OF BLOOD-BRAIN-BARRIER (BBB) OPENING WITH THE SONOCLOUD-9 IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING IV CARBOPLATIN
CTNI-37. SONOBIRD: A PHASE 3 TRIAL OF BLOOD-BRAIN-BARRIER (BBB) OPENING WITH THE SONOCLOUD-9 IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING IV CARBOPLATIN Open
This study aims to determine the efficacy of BBB disruption combined with carboplatin chemotherapy for patients with first recurrence of glioblastoma through a randomized, comparative, multicenter, phase 3 trial. The trial is open for enro…
View article: The Role of mTOR Signaling in Tumor-Induced Alterations to Neuronal Function in Diffusely Infiltrating Glioma
The Role of mTOR Signaling in Tumor-Induced Alterations to Neuronal Function in Diffusely Infiltrating Glioma Open
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that integrates metabolic and environmental signals to regulate cell growth and survival. In the central nervous system, mTOR plays a pivotal role in neuronal developmen…
View article: Socioeconomic Disparities in Patient-Reported Outcomes, Health Literacy, and Access to Care Among Patients With Primary Brain Tumors: Findings From the All of Us Research Program
Socioeconomic Disparities in Patient-Reported Outcomes, Health Literacy, and Access to Care Among Patients With Primary Brain Tumors: Findings From the All of Us Research Program Open
Purpose To understand the impact of socioeconomic status (SES) on patient-reported outcomes, health literacy, and access to care in primary malignant brain tumors (PMBT). Methods We performed a retrospective analysis of adults with PMBT us…
View article: Suppressing cortical glutamatergic neurons produces paradoxical interictal discharges and seizures
Suppressing cortical glutamatergic neurons produces paradoxical interictal discharges and seizures Open
Introduction Seizures are traditionally attributed to excessive excitation or deficient inhibition, yet recent clinical and slice data show they can also paradoxically arise when inhibition outweighs excitation. We chemogenetically suppres…
View article: Convection-enhanced delivery of dexamethasone in glioma suppresses myeloid inflammation while avoiding systemic toxicities
Convection-enhanced delivery of dexamethasone in glioma suppresses myeloid inflammation while avoiding systemic toxicities Open
Dexamethasone is widely used to control cerebral edema and inflammation in glioblastoma, but its benefits are limited by systemic toxicities and adverse prognostic associations. We evaluated local administration via convection-enhanced del…
View article: Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report
Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report Open
Glioblastoma (GBM) classification involves a combination of histological and molecular signatures including IDH1/2 mutation, TERT promoter mutation, and EGFR amplification. Non-canonical mutations such as BRAFV600E, found in 1-2% of GBMs, …
View article: Management of Asynchronous Multifocal Adult Glioblastoma with Loss of BRAFV600E-Mutant Clonality: A Case Report
Management of Asynchronous Multifocal Adult Glioblastoma with Loss of BRAFV600E-Mutant Clonality: A Case Report Open
Glioblastoma (GBM) classification involves a combination of histological and molecular signatures, including IDH1/2 mutation, TERT promoter mutation, and EGFR amplification. Non-canonical mutations such as BRAFV600E, found in 1–2% of GBMs,…
View article: TMIC-78. CHEMOTHERAPY INDUCED IMMUNOGENIC RESPONSE IN GLIOMA AND IMPLICATIONS FOR THERAPEUTIC STRATEGIES
TMIC-78. CHEMOTHERAPY INDUCED IMMUNOGENIC RESPONSE IN GLIOMA AND IMPLICATIONS FOR THERAPEUTIC STRATEGIES Open
INTRODUCTION Many glioblastoma (GBM) treatments fail because they treat tumor cells in isolation and ignore the surrounding microenvironment. In our phase 1b clinical trial of delivery of Topotecan (TPT) via Convection Enhanced Delivery (C…
View article: DDEL-17. INTRA-TUMORAL CONVECTION ENHANCED DELIVERY OF DEXAMETHASONE REDUCES INFLAMMATORY SIGNATURES AND EXTENDS SURVIVAL IN GBM MODEL
DDEL-17. INTRA-TUMORAL CONVECTION ENHANCED DELIVERY OF DEXAMETHASONE REDUCES INFLAMMATORY SIGNATURES AND EXTENDS SURVIVAL IN GBM MODEL Open
Dexamethasone is the most widely utilized drug for glioblastoma (GBM). However, systemic delivery of dexamethasone in GBM patients is associated with significant side effects and increasing doses with worse survival. Convection-enhanced de…
View article: CTIM-14. EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM)
CTIM-14. EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM) Open
Standard of care (SOC) for ndGBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. IGV-001 is an autologous biologic-device combination immunotherapy for the treatment of n…
View article: Glioma-Induced Alterations in Excitatory Neurons are Reversed by mTOR Inhibition
Glioma-Induced Alterations in Excitatory Neurons are Reversed by mTOR Inhibition Open
Gliomas are highly aggressive brain tumors characterized by poor prognosis and composed of diffusely infiltrating tumor cells that intermingle with non-neoplastic cells in the tumor microenvironment, including neurons. Neurons are increasi…
View article: Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients
Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients Open
Standard-of-care first-line therapy for patients with newly diagnosed glioblastoma (ndGBM) is maximal safe surgical resection, then concurrent radiotherapy and temozolomide, followed by maintenance temozolomide. IGV-001, the first product …
View article: Supplementary Tables S1-S3 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Supplementary Tables S1-S3 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas Open
Tables S1-S3
View article: Supplementary Tables S1-S3 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Supplementary Tables S1-S3 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas Open
Tables S1-S3
View article: Supplementary Figures S1-S6 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Supplementary Figures S1-S6 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas Open
Supplementary Data
View article: Data from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Data from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas Open
Purpose:While MGMT promoter methylation (mMGMT) is predictive of response to alkylating chemotherapy and guides treatment decisions in glioblastoma, its role in grade 2 and 3 glioma remains unclear. Recent data suggest that mMGMT is progno…
View article: RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS Open
Glioblastoma (GBM) is the most common primary brain malignancy in adults. Standard of care (SOC) for suspected GBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. Imvax h…
View article: Data from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Data from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas Open
Purpose:While MGMT promoter methylation (mMGMT) is predictive of response to alkylating chemotherapy and guides treatment decisions in glioblastoma, its role in grade 2 and 3 glioma remains unclear. Recent data suggest that mMGMT is progno…
View article: Supplementary Figures S1-S6 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Supplementary Figures S1-S6 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas Open
Supplementary Data
View article: <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
<i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas Open
Purpose: While MGMT promoter methylation (mMGMT) is predictive of response to alkylating chemotherapy and guides treatment decisions in glioblastoma, its role in grade 2 and 3 glioma remains unclear. Recent data suggest that mMGMT is progn…
View article: Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states
Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states Open
Glioblastoma (GBM) diffusely infiltrates the brain and intermingles with non-neoplastic brain cells, including astrocytes, neurons and microglia/myeloid cells. This complex mixture of cell types forms the biological context for therapeutic…